# | Title | Journal | Year | Citations |
---|
1 | American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography | Ca-A Cancer Journal for Clinicians | 2007 | 2,234 |
2 | Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer | New England Journal of Medicine | 2011 | 2,011 |
3 | Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain | Journal of Pain | 2009 | 1,960 |
4 | Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study | Lancet Oncology, The | 2016 | 1,279 |
5 | Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue | Journal of Clinical Apheresis | 2019 | 1,263 |
6 | Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial | Lancet Oncology, The | 2010 | 1,252 |
7 | Phase 3 trial of everolimus for metastatic renal cell carcinoma | Cancer | 2010 | 1,039 |
8 | Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology | Journal of the National Comprehensive Cancer Network: JNCCN | 2019 | 943 |
9 | Epidemiology of Renal Cell Carcinoma | European Urology | 2019 | 917 |
10 | Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet | Blood | 2009 | 856 |
11 | Chromatin accessibility pre-determines glucocorticoid receptor binding patterns | Nature Genetics | 2011 | 854 |
12 | Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology | Journal of the National Comprehensive Cancer Network: JNCCN | 2020 | 848 |
13 | Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology | Journal of the National Comprehensive Cancer Network: JNCCN | 2017 | 762 |
14 | Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology | Journal of the National Comprehensive Cancer Network: JNCCN | 2016 | 760 |
15 | Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology | Journal of the National Comprehensive Cancer Network: JNCCN | 2021 | 758 |
16 | The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia | Nature Genetics | 2017 | 693 |
17 | Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology | Journal of the National Comprehensive Cancer Network: JNCCN | 2019 | 672 |
18 | The global burden of women’s cancers: a grand challenge in global health | Lancet, The | 2017 | 666 |
19 | Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology | Journal of the National Comprehensive Cancer Network: JNCCN | 2020 | 633 |
20 | NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021 | Journal of the National Comprehensive Cancer Network: JNCCN | 2021 | 628 |
21 | Expansion of cancer care and control in countries of low and middle income: a call to action | Lancet, The | 2010 | 615 |
22 | Non–Small Cell Lung Cancer | Journal of the National Comprehensive Cancer Network: JNCCN | 2010 | 606 |
23 | Updated international consensus report on the investigation and management of primary immune thrombocytopenia | Blood Advances | 2019 | 593 |
24 | Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update | Journal of Clinical Oncology | 2021 | 580 |
25 | Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology | Journal of the National Comprehensive Cancer Network: JNCCN | 2021 | 564 |
26 | Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology | Journal of the National Comprehensive Cancer Network: JNCCN | 2022 | 562 |
27 | Prostate Cancer, Version 1.2016 | Journal of the National Comprehensive Cancer Network: JNCCN | 2016 | 544 |
28 | Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology | Journal of the National Comprehensive Cancer Network: JNCCN | 2022 | 530 |
29 | Guidelines on the Use of Therapeutic Apheresis in Clinical Practice—Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Sixth Special Issue | Journal of Clinical Apheresis | 2013 | 520 |
30 | Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology | Journal of the National Comprehensive Cancer Network: JNCCN | 2021 | 498 |
31 | Cowden Syndrome and the PTEN Hamartoma Tumor Syndrome: Systematic Review and Revised Diagnostic Criteria | Journal of the National Cancer Institute | 2013 | 483 |
32 | Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study | Annals of Oncology | 2013 | 481 |
33 | Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology | Journal of the National Comprehensive Cancer Network: JNCCN | 2021 | 477 |
34 | Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology | Journal of the National Comprehensive Cancer Network: JNCCN | 2017 | 451 |
35 | Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology | Journal of the National Comprehensive Cancer Network: JNCCN | 2022 | 445 |
36 | Randomized Trial of Denosumab in Patients Receiving Adjuvant Aromatase Inhibitors for Nonmetastatic Breast Cancer | Journal of Clinical Oncology | 2008 | 444 |
37 | Histopathologic Diagnosis of Chronic Graft-versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report | Biology of Blood and Marrow Transplantation | 2006 | 427 |
38 | Gastric Cancer, Version 2.2013 | Journal of the National Comprehensive Cancer Network: JNCCN | 2013 | 422 |
39 | Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel | Annals of Oncology | 2008 | 410 |
40 | NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017 | Journal of the National Comprehensive Cancer Network: JNCCN | 2017 | 408 |
41 | Managing Cancer Care During the COVID-19 Pandemic: Agility and Collaboration Toward a Common Goal | Journal of the National Comprehensive Cancer Network: JNCCN | 2020 | 401 |
42 | Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline | Journal of Clinical Oncology | 2021 | 395 |
43 | Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet | Blood | 2019 | 393 |
44 | Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology | Journal of the National Comprehensive Cancer Network: JNCCN | 2019 | 393 |
45 | Breast Cancer | Journal of the National Comprehensive Cancer Network: JNCCN | 2009 | 389 |
46 | Distress Management, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology | Journal of the National Comprehensive Cancer Network: JNCCN | 2019 | 385 |
47 | Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology | Journal of the National Comprehensive Cancer Network: JNCCN | 2020 | 383 |
48 | Cancer Yield of Mammography, MR, and US in High-Risk Women: Prospective Multi-Institution Breast Cancer Screening Study | Radiology | 2007 | 361 |
49 | Quantitative Fluoroestradiol Positron Emission Tomography Imaging Predicts Response to Endocrine Treatment in Breast Cancer | Journal of Clinical Oncology | 2006 | 357 |
50 | Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update | Journal of Clinical Oncology | 2018 | 357 |